MyChesCo on MSN15h
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has commenced its Phase 2a clinical trial for ATI-2138, an innovative oral covalent ...
FDA approves Ebglyss for moderate-to-severe atopic dermatitis
The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...
FDA Approves New Biologic Treatment For Atopic Dermatitis, Know How It Can Help Achieve Clear Skin
The FDA has approved Ebglyss (lebrikizumab-lbkz), a new biologic treatment for moderate-to-severe atopic dermatitis in people ...
The Pharma Letter20h
Atopic dermatitis market set for major growth
The atopic dermatitis (AD) market is projected to reach $16.7 billion by 2030, according to GlobalData. New therapies like ...
Everyday Health2d
Ebglyss, a New Biologic Treatment for Atopic Dermatitis, Gets FDA Approval
Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...
ELAN : FDA Oks Zenrelia, Once-Daily Oral JAK Inhibitor For Dogs With Allergic And Atopic Dermatitis
Elanco Animal Health Inc. (ELAN) announced the U.S. Food and Drug Administration has approved Zenrelia, a convenient once-daily oral ...
GlobalData on MSN1d
Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial
Aclaris Therapeutics has dosed the first subject in the Phase IIa clinical trial of ATI-2138 to treat moderate to severe ...
Medscape1d
Roflumilast Cream 0.15% Improves Atopic Dermatitis Symptoms in Phase 3 Studies
Roflumilast cream 0.15% was well tolerated and significantly improved symptoms in adults and children with mild to moderate atopic dermatitis (AD) in two phase 3 trials. The two phase 3 randomized ...
infectiousdiseaseadvisor.com16h
Pediatric Atopic Dermatitis: Dupilumab Normalizes Inflammatory Biomarkers
Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.
pulmonologyadvisor16h
Adbry Autoinjector Now Available for Adults With Atopic Dermatitis
A new single-dose autoinjector presentation of Adbry is now available for use in the treatment of moderate to severe atopic dermatitis.
Organon to buy skin therapy developer Dermavant for up to $1.2 billion
(Reuters) -Healthcare company Organon said on Wednesday it has agreed to acquire skin therapy developer Dermavant, a unit of Roivant, for up to $1.2 billion. Organon will make an upfront payment of ...